Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Study acronym: UPSTREAM SjD
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 1 entry
    • Trial sites expanded: 43 → 49 locations
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 3 of 6 entries
  2. Trial sites expanded: 38 → 43 locationsv11
  3. Trial sites expanded: 28 → 38 locationsv10
  4. Study sites: 26 to 28v9
  5. Study sites: 24 to 26v8
  6. Trial sites expanded: 18 → 24 locationsv7
  7. Trial sites expanded: 12 → 18 locations
    • Trial sites expanded: 8 → 12 locations
    v6
  8. Study sites: 8 to 12v5
  9. Trial sites expanded: 5 → 8 locationsv4
  10. Primary completion pushed from Jun 2028 to Dec 2028
    • Study completion pushed from Aug 2028 to Jan 2029
    • Study sites: 3 to 5
    v3
  11. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Feb 2026 to Feb 26, 2026
    v2
  12. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Trial Details
NCT Number NCT07404865
Lead Sponsor Vor Biopharma
Conditions
(from sponsor)		 Primary Sjogren's Disease
Related terms Sjogren's Syndrome
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov